Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PARP1-DOT1L transcription axis drives acquired resistance to PARP inhibitor in ovarian cancer

22 May 2024

Abstract excerpt

BACKGROUND: Poly (ADP-ribose) polymerase inhibitor (PARPi) resistance poses a significant challenge in ovarian carcinoma (OC). While the role of DOT1L in cancer and chemoresistance is acknowledged, its specific role in PARPi resistance remains unclear. This study aims to elucidate the molecular mechanism of DOT1L in PARPi resistance in OC patients. METHODS: This study analyzed the expression of DOT1L in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to Ovarian cancer diagnosis and treatment
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38778348
DOI: 10.1186/s12943-024-02025-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PARP1-DOT1L transcription axis drives acquired resistance to PARP inhibitor in ovarian cancerPMID 38778348Read ↗

HIF‐1α‐induced long noncoding RNA LINC02776 promotes drug resistance of ovarian cancer by increasing polyADP‐ribosylationSemantic proximity Read ↗

Epigenetic enzyme mutations as mediators of anti-cancer drug resistance.Semantic proximity Read ↗

Combinatorial targeting of menin and the histone methyltransferase DOT1L as a novel therapeutic strategy for treatment of chemotherapy-resistant ovarian cancerSemantic proximity Read ↗

MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancerSemantic proximity Read ↗

Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion MutationsSemantic proximity Read ↗

Analysis of the PARP1, ADP-Ribosylation, and TRIP12 Triad With Markers of Patient Outcome in Human Breast Cancer.Semantic proximity Read ↗

Machine learning-based prediction of response to PARP inhibition across cancer typesSemantic proximity Read ↗

LCP1 promotes ovarian cancer cell resistance to olaparib by activating the JAK2/STAT3 signalling pathwaySemantic proximity Read ↗

CYP1B1 promotes PARPi-resistance via histone H1.4 interaction and increased chromatin accessibility in ovarian cancerSemantic proximity Read ↗

PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, TalazoparibSemantic proximity Read ↗

Combinatorial targeting of a chromatin complex comprising Dot1L, menin and the tyrosine kinase BAZ1B reveals a new therapeutic vulnerability of endocrine therapy-resistant breast cancerSemantic proximity Read ↗

Genomic insights and therapeutic efficacy of PARP inhibitors in a high-LOH patient-derived xenograft from malignant transformation of ovarian teratoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.